Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

The sepsis model: an emerging hypothesis for the lethality of inhalation anthrax.

Coggeshall KM, Lupu F, Ballard J, Metcalf JP, James JA, Farris D, Kurosawa S.

J Cell Mol Med. 2013 Jul;17(7):914-20. doi: 10.1111/jcmm.12075. Epub 2013 Jun 7.

2.

Bacillus anthracis cell wall peptidoglycan but not lethal or edema toxins produces changes consistent with disseminated intravascular coagulation in a rat model.

Qiu P, Li Y, Shiloach J, Cui X, Sun J, Trinh L, Kubler-Kielb J, Vinogradov E, Mani H, Al-Hamad M, Fitz Y, Eichacker PQ.

J Infect Dis. 2013 Sep;208(6):978-89. doi: 10.1093/infdis/jit247. Epub 2013 Jun 3.

3.

Immune system paralysis by anthrax lethal toxin: the roles of innate and adaptive immunity.

Fukao T.

Lancet Infect Dis. 2004 Mar;4(3):166-70. Review.

PMID:
14998502
4.

Plasma bacterial and mitochondrial DNA distinguish bacterial sepsis from sterile systemic inflammatory response syndrome and quantify inflammatory tissue injury in nonhuman primates.

Sursal T, Stearns-Kurosawa DJ, Itagaki K, Oh SY, Sun S, Kurosawa S, Hauser CJ.

Shock. 2013 Jan;39(1):55-62. doi: 10.1097/SHK.0b013e318276f4ca.

5.

Evaluation of intravenous anthrax immune globulin for treatment of inhalation anthrax.

Mytle N, Hopkins RJ, Malkevich NV, Basu S, Meister GT, Sanford DC, Comer JE, Van Zandt KE, Al-Ibrahim M, Kramer WG, Howard C, Daczkowski N, Chakrabarti AC, Ionin B, Nabors GS, Skiadopoulos MH.

Antimicrob Agents Chemother. 2013 Nov;57(11):5684-92. doi: 10.1128/AAC.00458-13. Epub 2013 Aug 26.

6.

Lethal factor and anti-protective antigen IgG levels associated with inhalation anthrax, Minnesota, USA.

Sprenkle MD, Griffith J, Marinelli W, Boyer AE, Quinn CP, Pesik NT, Hoffmaster A, Keenan J, Juni BA, Blaney DD.

Emerg Infect Dis. 2014 Feb;20(2):310-4. doi: 10.3201/eid2002.130245.

7.

Sepsis and pathophysiology of anthrax in a nonhuman primate model.

Stearns-Kurosawa DJ, Lupu F, Taylor FB Jr, Kinasewitz G, Kurosawa S.

Am J Pathol. 2006 Aug;169(2):433-44.

8.

Combination therapy with antibiotics and anthrax immune globulin intravenous (AIGIV) is potentially more effective than antibiotics alone in rabbit model of inhalational anthrax.

Kammanadiminti S, Patnaikuni RK, Comer J, Meister G, Sinclair C, Kodihalli S.

PLoS One. 2014 Sep 16;9(9):e106393. doi: 10.1371/journal.pone.0106393. eCollection 2014.

9.

Interferon protects mice against inhalation anthrax.

Walberg K, Baron S, Poast J, Schwartz B, Izotova L, Pestka S, Peterson JW.

J Interferon Cytokine Res. 2008 Oct;28(10):597-601. doi: 10.1089/jir.2007.0143.

10.

The US capitol bioterrorism anthrax exposures: clinical epidemiological and immunological characteristics.

Doolan DL, Freilich DA, Brice GT, Burgess TH, Berzins MP, Bull RL, Graber NL, Dabbs JL, Shatney LL, Blazes DL, Bebris LM, Malone MF, Eisold JF, Mateczun AJ, Martin GJ.

J Infect Dis. 2007 Jan 15;195(2):174-84. Epub 2006 Dec 6.

PMID:
17191162
11.

Human monoclonal anti-protective antigen antibody completely protects rabbits and is synergistic with ciprofloxacin in protecting mice and guinea pigs against inhalation anthrax.

Peterson JW, Comer JE, Noffsinger DM, Wenglikowski A, Walberg KG, Chatuev BM, Chopra AK, Stanberry LR, Kang AS, Scholz WW, Sircar J.

Infect Immun. 2006 Feb;74(2):1016-24.

12.

Bacillus anthracis protective antigen kinetics in inhalation spore-challenged untreated or levofloxacin/ raxibacumab-treated New Zealand white rabbits.

Corey A, Migone TS, Bolmer S, Fiscella M, Ward C, Chen C, Meister G.

Toxins (Basel). 2013 Jan 14;5(1):120-38. doi: 10.3390/toxins5010120.

13.

Bacillus anthracis as an agent of bioterrorism: a review emphasizing surgical treatment.

Binkley CE, Cinti S, Simeone DM, Colletti LM.

Ann Surg. 2002 Jul;236(1):9-16. Review.

14.

Lethal factor, but not edema factor, is required to cause fatal anthrax in cynomolgus macaques after pulmonary spore challenge.

Hutt JA, Lovchik JA, Drysdale M, Sherwood RL, Brasel T, Lipscomb MF, Lyons CR.

Am J Pathol. 2014 Dec;184(12):3205-16. doi: 10.1016/j.ajpath.2014.08.008. Epub 2014 Oct 5.

15.

Toxin-deficient mutants of Bacillus anthracis are lethal in a murine model for pulmonary anthrax.

Heninger S, Drysdale M, Lovchik J, Hutt J, Lipscomb MF, Koehler TM, Lyons CR.

Infect Immun. 2006 Nov;74(11):6067-74. Epub 2006 Aug 21.

16.

Modeling the host response to inhalation anthrax.

Day J, Friedman A, Schlesinger LS.

J Theor Biol. 2011 May 7;276(1):199-208. doi: 10.1016/j.jtbi.2011.01.054. Epub 2011 Feb 3.

17.

Effective antiprotease-antibiotic treatment of experimental anthrax.

Popov SG, Popova TG, Hopkins S, Weinstein RS, MacAfee R, Fryxell KJ, Chandhoke V, Bailey C, Alibek K.

BMC Infect Dis. 2005 Apr 8;5:25.

18.

Parenteral Administration of Capsule Depolymerase EnvD Prevents Lethal Inhalation Anthrax Infection.

Negus D, Vipond J, Hatch GJ, Rayner EL, Taylor PW.

Antimicrob Agents Chemother. 2015 Dec;59(12):7687-92. doi: 10.1128/AAC.01547-15. Epub 2015 Oct 5.

19.

Detection of anthrax protective antigen (PA) using europium labeled anti-PA monoclonal antibody and time-resolved fluorescence.

Stoddard RA, Quinn CP, Schiffer JM, Boyer AE, Goldstein J, Bagarozzi DA, Soroka SD, Dauphin LA, Hoffmaster AR.

J Immunol Methods. 2014 Jun;408:78-88. doi: 10.1016/j.jim.2014.05.008. Epub 2014 May 22.

20.

Bacillus anthracis infections--new possibilities of treatment.

Żakowska D, Bartoszcze M, Niemcewicz M, Bielawska-Drózd A, Knap J, Cieślik P, Chomiczewski K, Kocik J.

Ann Agric Environ Med. 2015;22(2):202-7. doi: 10.5604/12321966.1152065. Review.

Supplemental Content

Support Center